Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Today, Andrew Pollard, Professor of Pediatric Infection and Immunity at the University of Oxford, and chief investigator of the trials of the ChAdOx1 nCoV-19 coronavirus vaccine, volunteered his time to help deliver live-saving Covid vaccinations at the newly opened NHS Vaccine Centre at the Kassam Stadium, Oxford.

Prof. Pollard preparing to deliver coronavirus vaccinations at the Kassam Stadium © Oxford Health NHS Foundation Trust

The first such large scale centre to be set up by Oxford Health NHS Foundation Trust, the Kassam Stadium, home to the city’s League One football side, will be open to the public by invite-only, seven days a week, from 8am to 8pm, as part of the national effort to vaccinate against COVID-19.  

Prof. Pollard said:  

‘To see a vaccination centre in Oxford delivering the vaccine that was developed in the city is a great moment. So much hard work has gone into getting to this stage from the researchers developing the vaccine and the Oxford Health team making all the arrangements to set up and run an efficient vaccination centre. Many volunteers from Oxfordshire took part in the clinical trials and it is a huge credit to their commitment that we can benefit from this vaccine today. 

‘We anticipate that the vaccination of as many people as possible as soon as possible will start to have a big impact on hospitalisations and is something everyone has been hoping for. However, vaccination is only one part of the story - people should continue to follow public health measures, such as observing the rules of lockdown, social distancing, wearing masks and washing their hands until we get the virus back under control.’ 

Read the full story on the University of Oxford website

Similar stories

PRINCIPLE Covid-19 treatments trial widens to under 50s and adds colchicine

Clinical Trials Coronavirus COVID-19 General Research

From today, the UK’s national priority platform trial of Covid-19 treatments for recovery at home launches its investigation of the gout drug colchicine, and expands for the first time to include adults of any age.

New data show vaccines reduce severe COVID-19 in older adults

Coronavirus COVID-19 Research

New data show both Oxford / AstraZeneca vaccine and the Pfizer-BioNTech vaccines significantly reduce severe COVID-19 in older adults.

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.